Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease-Reference-Cited by-同舟云学术

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease

Published:2024-08-27 Issue:9 Volume:3 Page:
ISSN:2766-5526
Container-title:NEJM Evidence
language:en
Short-container-title:NEJM Evidence

Author:

Ha Jeffrey T.¹²,Hiremath Swapnil³,Jun Min²,Green Suetonia C.⁴,Wheeler David C.⁵,Coyne Daniel W.⁶,Perkovic Vlado²,Badve Sunil V.²⁷

Affiliation:

1. Department of Renal Medicine, Wollongong Hospital, Wollongong, NSW, Australia

2. Renal and Metabolic Division, The George Institute for Global Health, University of New South Wales Medicine & Health, Sydney

3. Division of Nephrology, Department of Medicine, University of Ottawa, Ottawa

4. Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand

5. Department of Renal Medicine, University College London, London

6. Division of Nephrology, Washington University School of Medicine, St. Louis

7. Department of Renal Medicine, St. George Hospital, Sydney

Publisher

Massachusetts Medical Society

Reference40 articles.

1. United States Renal Data System. 2022 USRDS Annual Data Report: epidemiology of kidney disease in the United States. National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases Bethesda MD. 2022 (https://usrds-adr.niddk.nih.gov/2022).

2. Impact of Erythropoiesis-Stimulating Agents on Energy and Physical Function in Nondialysis CKD Patients With Anemia: A Systematic Review

3. Meta-analysis: Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney Disease

4. Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease

5. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis